Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews · Urology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 100%Moderate 0 · 0%High 0 · 0%

Gemcitabine vs BCG

Time to progression · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy

Gemcitabine may leads to lower time to progression compared with BCG (low certainty).

1 finding from 1 review

Intravesical gemcitabine for non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes only
HR 0.45 [0.27, 0.76]
1 study · 80 participants
Low

Gemcitabine vs mitomycin

Time to progression · patients with non‐muscle invasive bladder cancer

Gemcitabine showed no clear difference in time to progression compared with mitomycin (low certainty).

1 finding from 1 review

Intravesical gemcitabine for non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes only
HR 0.57 [0.32, 1.01]
1 study · 109 participants
Low

Gemcitabine vs Normal saline

Time to progression · patients with non‐muscle invasive bladder cancer

Gemcitabine showed no clear difference in time to progression (absolute effect size estimates based on… compared with saline (low certainty).

1 finding from 1 review

Intravesical gemcitabine for non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes only
HR 0.96 [0.19, 4.71]
2 studies · 654 participants
Low